$18.350
+3.222 (+17.56%)At close
- High
- 19.170
- Open
- 15.750
- VWAP
- 17.43
- Volume
- 145.63K
- Mkt Cap
- —
- Low
- 14.760
- Amount
- 2.54M
- EV/EBITDA, TTM
- 0.00
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
Valuation Metrics
MTRI FAQ — answered by Alphio AI
Mentari Therapeutics, Inc., a biotechnology company, develops and provides therapies for migraine prevention. The company's products include MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing; MT-002, an anti-CGRP; and anti-PACAP bispecific antibody designed to inhibit these complementary pathways. The company was incorporated in 2025 and is based in Sacramento, California.
Community
More ↗No posts yet
Sign up or log in to join the discussionRelated articles
- Dollar-Cost Averaging vs Lump Sum: How to Invest Cash in a Volatile, High-Yield 2026 MarketDollar cost averaging vs lump sum in a volatile 2026 market: what Vanguard's research shows, how 4%+ T-bill yields change the math, and how to build a plan.
- Stock Market Outlook 2027: What Wall Street's S&P 500 Forecasts Really Tell InvestorsStock market outlook 2027: what Goldman, UBS, BofA and bears forecast for the S&P 500, the earnings math behind targets, and how to plan for any scenario.
- REITs and Rising Interest Rates in 2026: Why Real Estate Stocks Are Holding Up and Where the Risks AHow rising interest rates affect REITs in 2026: why REITs are up despite Fed hikes, which sectors hold up, how to value REITs and build a rate-aware allocation.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.